Clinical Trial Search

Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 4; 8; 0; 0 participants

Primary: Premature Infant Pain Profile — -0.60; 1.43 units on a scale

Primary: PVD Induction — 0; 20; 13.3; 30.8 percentage of participants — p=0.131

Primary: Number of Participants With Engraftment — 23 Participants

Primary: Measure of Psychomotor Function Using Speed and Coordination on the CogScreen Pathfinder Number (PFN) Test in Subjects Treated With Alcohol Compared to Alcohol Placebo…

Primary: DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29

Primary: Proportion of Subjects With Total PVD at the First Day 14 Post-injection Visit (Vitreous Detachment to the Equator) as Determined by Masked Central Reading Center (CRC)…

Primary: Number of Participants With the Indicated Grade 4 Hematology Toxicities Following Iodine-131 Anti-B1 Antibody — 1; 1; 1; 1 participants

Primary: Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day…

Primary: Progression-free Survival Rate — 5.3 percentage of participants

Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants

Primary: No.of Gd+ Lesions From Week 8 to Week 24 — 46; 33; 5; 13 participants — p=0.04

Primary: Pre-bronchodilator FEV1 at the Clinic — 0.16; 0.19; 0.19; 0.15 Liters

Primary: Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC) — 29.9 percentage of participants

Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71